{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.5","upperLimit":"88.3","value":"80.4"},{"groupId":"OG001","lowerLimit":"78.1","upperLimit":"91.7","value":"84.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Tolerability was defined as having received 90% of the radiation dose, 95% of the cetuximab loading dose, and at least 4 weeks of cetuximab and cisplatin or docetaxel at doses 95% of the protocol prescription. The percentage of patients determined to be tolerant of treatment are shown.","dispersionType":"95% Confidence Interval","groups":[{"description":"Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.","id":"OG000","title":"RT+Cisplatin+Cetuximab"},{"description":"Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.","id":"OG001","title":"RT+Docetaxel+Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started protocol treatment and did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From start of treatment to end of treatment (protocol treatment lasts seven weeks).","title":"Treatment Tolerance","type":"SECONDARY","unitOfMeasure":"percentage of participants"}